Amylyx Pharmaceuticals (NASDAQ:AMLX) Now Covered by Analysts at Mizuho

Mizuho began coverage on shares of Amylyx Pharmaceuticals (NASDAQ:AMLX – Get Rating) in a report released on Thursday, The Fly reports. The firm issued a buy rating and a $52.00 target price on the stock. Several other analysts also recently weighed in on AMLX. HC Wainwright reissued a buy rating and issued a $50.00 target […]

Related Keywords

United States ,America ,Gina Mazzariello ,Amylyx Pharmaceuticals Inc ,Goldman Sachs Group ,Voya Investment Management ,Institutional Trading Of Amylyx Pharmaceuticals ,Amylyx Pharmaceuticals ,News Ratings For Amylyx Pharmaceuticals Daily ,Amylyx Pharmaceuticals Stock ,Citigroup ,Amylyx Pharmaceuticals Company Profile ,Life Insurance Co ,Metlife Investment Management ,Tang Capital Management ,Analyst Recommendations For Amylyx Pharmaceuticals ,Get Rating ,Moderate Buy ,Morningside Venture Investment ,Life Insurance ,Life Investment Management ,Investment Management ,Amylyx Pharmaceuticals Daily ,Nasdaq Amlx ,Amlx ,Medical ,Initiated Coverage ,Mizuho ,